Mymetics Corp (MYMX)

[Work Harder]

Virosome Vaccines: Articles by Pierre van Damme

Crucell Holland BV, Leiden, The Netherlands

Crucell Switzerland AG, Bern, Switzerland

Janssen Vaccines AG, Switzerland

Janssen Research & Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium

Medical Department, Johnson & Johnson, Horsham, PA, United States

University of Antwerp, Belgium

Ghent University, Ghent, Belgium

https://www.expertscape.com/ar/vaccines%2C+virosome/a/Van+Damme%2C+Pierre

Intradermal delivery significantly improved influenza vaccine immunogenicity compared with intramuscular delivery. Triple dose (45µg) virosomal vaccine did not demonstrate any benefit on vaccine's immunogenicity over 15µg commercial presentation. All treatments were generally safe and well-tolerated.

Vaccination of children with two doses of Epaxal Junior confers a real-time protection of at least 5.5 years. This protection is estimated to last approximately 25 years. Younger children showed lower antibody titers and a faster antibody decline than older children. Additional follow-up studies are needed beyond 5.5 years to further assess the long-term immunogenicity of Epaxal Junior.

Now where is that Dust Mite Trial :}